Patents by Inventor Robert A. Lazarus

Robert A. Lazarus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HGF ? chain variants
    Patent number: 8110377
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20110177058
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: December 22, 2010
    Publication date: July 21, 2011
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • VARIANT HHIP1 PROTEIN AND METHODS AND USES THEREOF
    Publication number: 20110129457
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Application
    Filed: June 1, 2009
    Publication date: June 2, 2011
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • HGF BETA CHAIN VARIANTS
    Publication number: 20100210826
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • HGF beta chain variants
    Patent number: 7737115
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: June 15, 2010
    Assignee: Genetech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20100040634
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • HUMAN DNASE I HYPERACTIVE VARIANTS
    Publication number: 20080293121
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Application
    Filed: July 1, 2008
    Publication date: November 27, 2008
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • CRYSTAL STRUCTURE OF THE HEPATOCYTE GROWTH FACTOR AND METHODS OF USE
    Publication number: 20080195366
    Abstract: The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF ?) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
    Type: Application
    Filed: March 27, 2008
    Publication date: August 14, 2008
    Inventors: Charles W. Eigenbrot, Daniel K. Kirchhofer, Robert A. Lazarus
  • Human DNase I hyperactive variants
    Patent number: 7407785
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Enzymes for the production of 2-keto-L-gulonic acid
    Patent number: 7256027
    Abstract: Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: August 14, 2007
    Assignee: Rutgers, the State University of New Jersey
    Inventors: Robert A. Lazarus, Mark Hurle, Stephen Anderson, David B. Powers
  • FVIIa antagonists
    Patent number: 7164002
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: January 16, 2007
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Henry R. Maun
  • FVIIa antagonists
    Patent number: 7084109
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: August 1, 2006
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Charles Eigenbrot, Robert A. Lazarus
  • FVIIa antagonists
    Publication number: 20040087767
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa , FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: January 30, 2003
    Publication date: May 6, 2004
    Applicant: GENENTECH, INC.
    Inventors: Robert A. Lazarus, Henry R. Maun
  • FVIIa antagonists
    Publication number: 20030119727
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: July 25, 2002
    Publication date: June 26, 2003
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Charles Eigenbrot, Robert A. Lazarus
  • Human DNase I hyperactive variants
    Publication number: 20020173025
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Application
    Filed: November 7, 2001
    Publication date: November 21, 2002
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Human DNase I hyperactive variants
    Patent number: 6391607
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: May 21, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Human DNase I variants
    Patent number: 6348343
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer
  • Human DNase I variants
    Publication number: 20010041360
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Application
    Filed: February 28, 2001
    Publication date: November 15, 2001
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer
  • Pharmaceutical compositions containing ecotin and homologs thereof
    Patent number: 6113896
    Abstract: A potent serine protease inhibitor capable of inhibiting Factor Xa, Factor XIIa, plasma kallikrein, and human leukocyte elastase is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor Xa, Factor XIIa, plasma kallikrein, or HLE is indicated.
    Type: Grant
    Filed: October 4, 1994
    Date of Patent: September 5, 2000
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Mark S. Dennis, Jana Seymour Ulmer
  • Enzymes for the production of 2-keto-L-gulonic acid
    Patent number: 5912161
    Abstract: Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: June 15, 1999
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Robert A. Lazarus, Mark Hurle, Stephen Anderson, David B. Powers